106 related articles for article (PubMed ID: 29187703)
1. Paraganglioma as a risk factor for bone metastasis.
Yokomoto-Umakoshi M; Umakoshi H; Tsuiki M; Ogasawara T; Hamanaka-Hiroshima K; Tanabe A; Tagami T; Shimatsu A; Naruse M
Endocr J; 2018 Mar; 65(3):253-260. PubMed ID: 29187703
[TBL] [Abstract][Full Text] [Related]
2. Bone metastases and skeletal-related events in patients with malignant pheochromocytoma and sympathetic paraganglioma.
Ayala-Ramirez M; Palmer JL; Hofmann MC; de la Cruz M; Moon BS; Waguespack SG; Habra MA; Jimenez C
J Clin Endocrinol Metab; 2013 Apr; 98(4):1492-7. PubMed ID: 23436918
[TBL] [Abstract][Full Text] [Related]
3. Clinical Predictors of Malignancy in Patients with Pheochromocytoma and Paraganglioma.
Dhir M; Li W; Hogg ME; Bartlett DL; Carty SE; McCoy KL; Challinor SM; Yip L
Ann Surg Oncol; 2017 Nov; 24(12):3624-3630. PubMed ID: 28884434
[TBL] [Abstract][Full Text] [Related]
4. Emerging Treatments for Advanced/Metastatic Pheochromocytoma and Paraganglioma.
Ilanchezhian M; Jha A; Pacak K; Del Rivero J
Curr Treat Options Oncol; 2020 Aug; 21(11):85. PubMed ID: 32862332
[TBL] [Abstract][Full Text] [Related]
5. Malignant pheochromocytoma and paraganglioma: a population level analysis of long-term survival over two decades.
Goffredo P; Sosa JA; Roman SA
J Surg Oncol; 2013 May; 107(6):659-64. PubMed ID: 23233320
[TBL] [Abstract][Full Text] [Related]
6. TAKOTSUBO-LIKE CARDIOMYOPATHY IN A LARGE COHORT OF PATIENTS WITH PHEOCHROMOCYTOMA AND PARAGANGLIOMA.
Gagnon N; Mansour S; Bitton Y; Bourdeau I
Endocr Pract; 2017 Oct; 23(10):1178-1192. PubMed ID: 28704094
[TBL] [Abstract][Full Text] [Related]
7. Malignant Pheochromocytoma and Paraganglioma: 272 Patients Over 55 Years.
Hamidi O; Young WF; Iñiguez-Ariza NM; Kittah NE; Gruber L; Bancos C; Tamhane S; Bancos I
J Clin Endocrinol Metab; 2017 Sep; 102(9):3296-3305. PubMed ID: 28605453
[TBL] [Abstract][Full Text] [Related]
8. Outcomes of patients with metastatic phaeochromocytoma and paraganglioma: A systematic review and meta-analysis.
Hamidi O; Young WF; Gruber L; Smestad J; Yan Q; Ponce OJ; Prokop L; Murad MH; Bancos I
Clin Endocrinol (Oxf); 2017 Nov; 87(5):440-450. PubMed ID: 28746746
[TBL] [Abstract][Full Text] [Related]
9. Overexpression of the insulin-like growth factor 1 receptor (IGF-1R) is associated with malignancy in familial pheochromocytomas and paragangliomas.
Fernandez MC; Martin A; Venara M; Calcagno Mde L; Sansó G; Quintana S; Chemes HE; Barontini M; Pennisi PA
Clin Endocrinol (Oxf); 2013 Nov; 79(5):623-30. PubMed ID: 23506534
[TBL] [Abstract][Full Text] [Related]
10. Novel SDHB and TMEM127 Mutations in Patients with Pheochromocytoma/Paraganglioma Syndrome.
Patócs A; Lendvai NK; Butz H; Liko I; Sapi Z; Szucs N; Toth G; Grolmusz VK; Igaz P; Toth M; Rácz K
Pathol Oncol Res; 2016 Oct; 22(4):673-9. PubMed ID: 26960314
[TBL] [Abstract][Full Text] [Related]
11. Pheochromocytoma and paraganglioma in cyanotic congenital heart disease.
Opotowsky AR; Moko LE; Ginns J; Rosenbaum M; Greutmann M; Aboulhosn J; Hageman A; Kim Y; Deng LX; Grewal J; Zaidi AN; Almansoori G; Oechslin E; Earing M; Landzberg MJ; Singh MN; Wu F; Vaidya A
J Clin Endocrinol Metab; 2015 Apr; 100(4):1325-34. PubMed ID: 25581599
[TBL] [Abstract][Full Text] [Related]
12. Risk factors for skeletal-related events (SREs) and factors affecting SRE-free survival for nonsmall cell lung cancer patients with bone metastases.
Ulas A; Bilici A; Durnali A; Tokluoglu S; Akinci S; Silay K; Oksuzoglu B; Alkis N
Tumour Biol; 2016 Jan; 37(1):1131-40. PubMed ID: 26276360
[TBL] [Abstract][Full Text] [Related]
13. Pathology and genetics of phaeochromocytoma and paraganglioma.
Turchini J; Cheung VKY; Tischler AS; De Krijger RR; Gill AJ
Histopathology; 2018 Jan; 72(1):97-105. PubMed ID: 29239044
[TBL] [Abstract][Full Text] [Related]
14. Catecholamine metabolism in paraganglioma and pheochromocytoma: similar tumors in different sites?
Grouzmann E; Tschopp O; Triponez F; Matter M; Bilz S; Brändle M; Drechser T; Sigrist S; Zulewski H; Henzen C; Fischli S; Abid K
PLoS One; 2015; 10(5):e0125426. PubMed ID: 25946206
[TBL] [Abstract][Full Text] [Related]
15. Risk Factors for Developing Skeletal-Related Events in Breast Cancer Patients With Bone Metastases Undergoing Treatment With Bone-Modifying Agents.
Tanaka R; Yonemori K; Hirakawa A; Kinoshita F; Takahashi N; Hashimoto J; Kodaira M; Yamamoto H; Yunokawa M; Shimizu C; Fujimoto M; Fujiwara Y; Tamura K
Oncologist; 2016 Apr; 21(4):508-13. PubMed ID: 26975863
[TBL] [Abstract][Full Text] [Related]
16. Composite Pheochromocytoma/Paraganglioma-Ganglioneuroma: A Clinicopathologic Study of Eight Cases with Analysis of Succinate Dehydrogenase.
Gupta S; Zhang J; Erickson LA
Endocr Pathol; 2017 Sep; 28(3):269-275. PubMed ID: 28752484
[TBL] [Abstract][Full Text] [Related]
17. Germline mutations and genotype-phenotype correlations in patients with apparently sporadic pheochromocytoma/paraganglioma in Korea.
Kim JH; Seong MW; Lee KE; Choi HJ; Ku EJ; Bae JH; Park SS; Choi SH; Kim SW; Shin C; Kim SY
Clin Genet; 2014 Nov; 86(5):482-6. PubMed ID: 24134185
[TBL] [Abstract][Full Text] [Related]
18. [Pheochromocytoma and paraganglioma: basics for the general practitioner].
Loosli N; Köhler BB; Pechère-Bertschi A; Karenovics W; Triponex F
Rev Med Suisse; 2014 Sep; 10(441):1650-2, 1654-5. PubMed ID: 25322623
[TBL] [Abstract][Full Text] [Related]
19. Pheochromocytoma and paraganglioma in patients with neurofibromatosis type 1.
Gruber LM; Erickson D; Babovic-Vuksanovic D; Thompson GB; Young WF; Bancos I
Clin Endocrinol (Oxf); 2017 Jan; 86(1):141-149. PubMed ID: 27460956
[TBL] [Abstract][Full Text] [Related]
20. Phenylethanolamine N-methyltransferase downregulation is associated with malignant pheochromocytoma/paraganglioma.
Lee SE; Oh E; Lee B; Kim YJ; Oh DY; Jung K; Choi JS; Kim J; Kim SJ; Yang JW; An J; Oh YL; Choi YL
Oncotarget; 2016 Apr; 7(17):24141-53. PubMed ID: 27007161
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
